-DOCSTART- -X- O
CD8+ -X- _ O
T -X- _ O
cells -X- _ O
have -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
control -X- _ O
HSV-2 -X- _ O
infection. -X- _ O
However -X- _ O
, -X- _ O
limited -X- _ O
information -X- _ O
has -X- _ O
been -X- _ O
available -X- _ O
on -X- _ O
CD8+ -X- _ O
T -X- _ O
cell -X- _ O
epitopes -X- _ O
or -X- _ O
the -X- _ O
functionality -X- _ O
of -X- _ O
antigen -X- _ O
specific -X- _ O
T -X- _ O
cells -X- _ O
during -X- _ O
infection -X- _ O
or -X- _ O
following -X- _ O
immunization -X- _ O
with -X- _ O
experimental -X- _ O
vaccines. -X- _ O
Peptide -X- _ O
panels -X- _ O
from -X- _ O
HSV-2 -X- _ O
proteins -X- _ O
ICP27 -X- _ O
, -X- _ O
VP22 -X- _ O
and -X- _ O
VP13 -X- _ O
/ -X- _ O
14 -X- _ O
were -X- _ O
selected -X- _ O
from -X- _ O
in -X- _ O
silico -X- _ O
predictions -X- _ O
of -X- _ O
binding -X- _ O
to -X- _ O
human -X- _ O
HLA-A*0201 -X- _ O
and -X- _ O
mouse -X- _ O
H-2Kd -X- _ O
, -X- _ O
Ld -X- _ O
and -X- _ O
Dd -X- _ O
molecules. -X- _ O
Nine -X- _ B-Intervention
previously -X- _ I-Intervention
uncharacterized -X- _ I-Intervention
CD8+ -X- _ I-Intervention
T -X- _ I-Intervention
cell -X- _ I-Intervention
epitopes -X- _ I-Intervention
were -X- _ O
identified -X- _ O
from -X- _ O
HSV-2 -X- _ B-Patient
infected -X- _ I-Patient
BALB -X- _ I-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice. -X- _ I-Patient
HSV-2 -X- _ B-Outcome
specific -X- _ I-Outcome
peptide -X- _ I-Outcome
sequences -X- _ I-Outcome
stabilized -X- _ I-Outcome
HLA- -X- _ I-Outcome
A*02 -X- _ I-Outcome
surface -X- _ I-Outcome
expression -X- _ I-Outcome
with -X- _ I-Outcome
intermediate -X- _ I-Outcome
or -X- _ I-Outcome
high -X- _ I-Outcome
affinity -X- _ I-Outcome
binding. -X- _ I-Outcome
Peptide -X- _ O
specific -X- _ O
CD8+ -X- _ O
human -X- _ O
T -X- _ O
cell -X- _ O
lines -X- _ O
from -X- _ O
peripheral -X- _ O
blood -X- _ O
lymphocytes -X- _ O
were -X- _ O
generated -X- _ O
from -X- _ O
a -X- _ O
HLA-A*02+ -X- _ O
donor. -X- _ O
High -X- _ B-Outcome
frequencies -X- _ I-Outcome
of -X- _ I-Outcome
peptide -X- _ I-Outcome
specific -X- _ I-Outcome
CD8+ -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ I-Outcome
elicited -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
by -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccination -X- _ I-Outcome
with -X- _ I-Outcome
ICP27 -X- _ I-Outcome
, -X- _ I-Outcome
VP22 -X- _ I-Outcome
and -X- _ I-Outcome
VP13 -X- _ I-Outcome
/ -X- _ I-Outcome
14 -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
demonstrated -X- _ I-Outcome
by -X- _ I-Outcome
CD107a -X- _ I-Outcome
mobilization. -X- _ I-Outcome
Vaccine -X- _ I-Outcome
driven -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
displayed -X- _ I-Outcome
a -X- _ I-Outcome
more -X- _ I-Outcome
focused -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
viral -X- _ I-Outcome
infection. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
vaccination -X- _ B-Outcome
with -X- _ I-Outcome
ICP27 -X- _ I-Outcome
reduced -X- _ I-Outcome
viral -X- _ I-Outcome
shedding -X- _ I-Outcome
and -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
clinical -X- _ I-Outcome
impact -X- _ I-Outcome
of -X- _ I-Outcome
disease. -X- _ I-Outcome
In -X- _ O
conclusion -X- _ O
, -X- _ O
this -X- _ O
study -X- _ O
describes -X- _ O
novel -X- _ B-Intervention
HSV-2 -X- _ I-Intervention
epitopes -X- _ I-Intervention
eliciting -X- _ B-Outcome
strong -X- _ I-Outcome
CD8+ -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
that -X- _ O
may -X- _ O
facilitate -X- _ O
epitope -X- _ O
based -X- _ O
vaccine -X- _ O
design -X- _ O
and -X- _ O
aid -X- _ O
immunomonitoring -X- _ O
of -X- _ O
antigen -X- _ O
specific -X- _ O
T -X- _ O
cell -X- _ O
frequencies -X- _ O
in -X- _ O
preclinical -X- _ O
and -X- _ O
clinical -X- _ O
settings -X- _ O
. -X- _ O

